REVIEW article
Front. Immunol.
Sec. Antigen Presenting Cell Biology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1656937
From Promise to Practice: Evaluating the Clinical Impact of FcRn Inhibition in IgG-Mediated Autoimmune Rheumatic Diseases
Provisionally accepted
Shui Lian Yu1*
Chu Wei Yang1Ting Xia1
Qing Tan2Li Gang Jie2Ai Ju Lou3
Xiao Xiao Li1
Maierhaba Maitiyaer1
Wen Hui Huang1
Yu Zheng1- 1The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- 2Zhujiang Hospital of Southern Medical University, Guangzhou, China
- 3Liwan Central Hospital of Guangzhou, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The neonatal Fragment Crystallizable receptor (FcRn) plays a central role in maintaining immunoglobulin (Ig) G homeostasis by protecting IgG from lysosomal degradation and regulating its transcytosis. In recent years, pharmacological inhibition of FcRn has emerged as a promising therapeutic strategy for IgG-mediated aumhctoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, anti-Neutrophil Cytoplasmic Antibodies (ANCA) -associated vasculitis, and others. By accelerating the catabolism of circulating IgG,
Keywords: neonatal Fc receptor, IgG homeostasis, Autoimmune Diseases, FcRn inhibitors, efgartigimod
Received: 30 Jun 2025; Accepted: 12 Aug 2025.
Copyright: © 2025 Yu, Yang, Xia, Tan, Jie, Lou, Li, Maitiyaer, Huang and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shui Lian Yu, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.